ACC 2018 | DEFINE-FLAIR Sub-Analysis: iFR More Comfortable, Faster, and Much Cheaper

Using instantaneous wave-free ratio (iFR) to guide decisions on revascularization of intermediate lesions is cheaper than using fractional flow reserve (FFR). Based on costs from the DEFINE-FLAIR trial, researchers estimate the difference to be almost USD 1000.

This should not be seen as good news for any given technology (iFR, in this case), but for physiologic assessment as a general concept. Many more interventional cardiologists need to start using physiologic assessment as a standard course of action in their cath labs, because there is much evidence that it improves outcomes.

 

FFR requires maximum hyperemia, which is achieved by using adenosine—with its associated side effects and costs. On the other hand, iFR calculates the pressure gradient of a lesion during diastole, immediately after the dicrotic wave, when physiologic resistance is minimum. That renders unnecessary the use of hyperemic agents.


Read also: NOTION: 5-Year Outcomes of TAVR vs. Surgery in Low-Risk Patients are Promising.


Last year, DEFINE-FLAIR and iFR-SWEDEHEART results proved the noninferiority of iFR in terms of events compared with FFR measurement.

 

The difference in terms of costs is driven by the fact that FFR-guided procedures identified more significant lesions that required treatment. More time must go by for the assessment of this aspect. If, in the future, some lesions left untreated with iFR require reintervention, the equation might be inverted by the late catch-up phenomenon. The opposite might also turn out to be true: less stenting with iFR might derive in less restenosis and less future thrombosis.

 

Original title: Comparative Cost-Effectiveness of the Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve in Coronary Revascularization Decision-Making.

Presenter: Patel MR.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....